CA2366785A1 - Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble - Google Patents

Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble Download PDF

Info

Publication number
CA2366785A1
CA2366785A1 CA002366785A CA2366785A CA2366785A1 CA 2366785 A1 CA2366785 A1 CA 2366785A1 CA 002366785 A CA002366785 A CA 002366785A CA 2366785 A CA2366785 A CA 2366785A CA 2366785 A1 CA2366785 A1 CA 2366785A1
Authority
CA
Canada
Prior art keywords
tnfr
administered
patient
group
per week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002366785A
Other languages
English (en)
Other versions
CA2366785C (fr
Inventor
Barbara K. Finck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366785A1 publication Critical patent/CA2366785A1/fr
Application granted granted Critical
Publication of CA2366785C publication Critical patent/CA2366785C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des méthodes de traitement de troubles d'ordre médical caractérisés par de niveaux élevés ou par une expression anormale de facteur de nécrose tumorale alpha par l'administration d'un antagoniste du facteur de nécrose tumorale alpha, par exemple un récepteur du facteur de nécrose tumorale recombinant (TNFR:Fc)
CA2366785A 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble Expired - Lifetime CA2366785C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US13007499P 1999-04-19 1999-04-19
US60/130,074 1999-04-19
US13432099P 1999-05-14 1999-05-14
US60/134,320 1999-05-14
US14395999P 1999-07-15 1999-07-15
US60/143,959 1999-07-15
US14823499P 1999-08-11 1999-08-11
US60/148,234 1999-08-11
US37382899A 1999-08-13 1999-08-13
US09/373,828 1999-08-13
US16467699P 1999-11-10 1999-11-10
US60/164,676 1999-11-10
US18486400P 2000-02-25 2000-02-25
US60/184,864 2000-02-25
PCT/US2000/010565 WO2000062790A2 (fr) 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble

Publications (2)

Publication Number Publication Date
CA2366785A1 true CA2366785A1 (fr) 2000-10-26
CA2366785C CA2366785C (fr) 2012-02-07

Family

ID=27568861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366785A Expired - Lifetime CA2366785C (fr) 1999-04-19 2000-04-19 Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble

Country Status (4)

Country Link
EP (1) EP1171148A2 (fr)
AU (1) AU4363200A (fr)
CA (1) CA2366785C (fr)
WO (1) WO2000062790A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2399436A1 (fr) * 2000-02-10 2001-08-16 Loran Marie Killar Procede destine a traiter ou a inhiber des lesions ou des morts cellulaires
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
WO2003009864A1 (fr) * 2001-07-23 2003-02-06 Genset S.A. Agonistes et antagonistes de disomet pour le traitement de troubles metaboliques
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
EP1946776B1 (fr) 2002-02-27 2017-01-18 Immunex Corporation Composition tnfr-fc stabilisée comportant une arginine
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
WO2007019573A2 (fr) 2005-08-09 2007-02-15 Zymogenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
WO2007082542A1 (fr) * 2006-01-17 2007-07-26 Astion Pharma A/S Préparations comprenant de l’oxaprozine et un analogue de vitamine d3 et leur emploi dans la fabrication d'un médicament pour le traitement du psoriasis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007121538A1 (fr) * 2006-04-26 2007-11-01 Plasma Ventures Pty Ltd Produit sanguin anti-inflammatoire et procede d'utilisation
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2012143418A1 (fr) 2011-04-20 2012-10-26 Sandoz Ag Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
MX421100B (es) 2011-07-01 2025-02-10 Biogen Ma Inc Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
CA2904035A1 (fr) 2013-03-06 2014-09-12 Protalix Ltd. Polypeptides inhibiteurs de tnf alpha, polynucleotides codant pour ceux-ci, cellules exprimant ceux-ci et leurs procedes de production
WO2016149139A1 (fr) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Composition contenant un polypeptide anti-tnf-alpha et utilisation
WO2017123672A1 (fr) * 2016-01-12 2017-07-20 Lawrence Chan Polythérapie pour le traitement de maladies inflammatoires
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0942740T3 (da) * 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
EP0869179A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Récepteur en rapport avec la nécrose des tumeurs, TR7

Also Published As

Publication number Publication date
WO2000062790A8 (fr) 2001-08-02
WO2000062790A2 (fr) 2000-10-26
EP1171148A2 (fr) 2002-01-16
CA2366785C (fr) 2012-02-07
AU4363200A (en) 2000-11-02
WO2000062790A3 (fr) 2001-07-12

Similar Documents

Publication Publication Date Title
KR101186029B1 (ko) 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도
Loeser Herpes zoster and postherpetic neuralgia
Crolle et al. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation
US4822802A (en) Method of fentanly administration for postoperative pain relief
JP5646617B2 (ja) 多発性硬化症の治療のための組成物および方法
CA2452874A1 (fr) Administration orale de 6-hydroxy-oxymorphone utilise en tant qu'analgesique
DK2002826T3 (da) Transdermalt indgivelsessystem med titrerbar dosering
ES2194025T3 (es) Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
US6903100B2 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
Gupta et al. Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current
Oakley et al. Randomized placebo-controlled trial of local anaesthetic infusion in day-case inguinal hernia repair
WO1994026270A1 (fr) Systemes therapeutiques transdermiques pour l'administration d'agonistes de la serotonine
JP2024542777A5 (fr)
Cortes et al. Chemotherapy for head and neck cancer relapsing after radiotherapy
Chiran et al. Intravenous laser blood irradiation and tocilizumab in a patient with juvenile arthritis
Streifler et al. Calcitonin for pseudoclaudication in lumbar spinal stenosis
Baglivo et al. Potential therapeutic role of pharmacological sympathectomy in Martorell ulcer
WO2003082213A3 (fr) Compositions et procedes de distribution d'agents pharmaceutiquement actifs au moyen de nanoparticules
RU2539418C1 (ru) Способ лечения местно-распространенного рака орофарингеальной зоны
AU2015305430A1 (en) Method for treating hyperhidrosis
Valley et al. Relief of recurrent upper extremity sympathetically-maintained pain with contralateral sympathetic blocks: evidence for crossover sympathetic innervation?
GB2595077A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
KR102026321B1 (ko) 만성 통증 완화에 이용되는 점막 관통 약물 전달 장치
Wong et al. Pentamorphone for management of postoperative pain
RU2146884C1 (ru) Способ лечения диффузного токсического зоба

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200419